(¿Â¶óÀÎ) 2020 KALC International Conference : 2020-11-20±³À°ÀÏÀÚ : 2020-11-20
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ) 2020 KALC International Conference ÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
´ã´çÀÚ : ½ÉÇöÁ¤
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, °áÇÙ°ú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 600¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 60,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 08:00~08:40 Tumor Infiltrating Lymphocytes and the Microenvironment as Biomarkers for Lung Cancer David Rimm(Yale University School of Medicine)
ÈÞ½Ä 11¿ù 20ÀÏ 08:40~08:50 Break ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 08:50~09:30 Present and Future Perspectives of First-Line Checkpoint Inhibitor for Stage IV Nonsmall Cell Lung Cancer David Carbone(The Ohio State University)
ÈÞ½Ä 11¿ù 20ÀÏ 09:30~09:40 Break ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 09:40~10:05 Harms, benefits and cost effectiveness of lc screening Harry J. de Koning(Erasmus University Medical Center)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 10:05~10:30 LDCT Screening in Non-Smokers in Taiwan Pan-Chyr Yang(National Taiwan University)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 10:30~10:55 Imaging Biomarkers in Lung Cancer Screening ±¸Áø¸ð(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 10:55~11:20 Liquid Biomarkers in Lung Cancer Screening À̰迵(°Ç±¹ÀÇ´ë)
ÈÞ½Ä 11¿ù 20ÀÏ 11:20~11:30 Break ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 11:30~12:20 Is it time for a paradigm shift in first line treatment of advanced NSCLC? ±èÇý·Ã(¿¬¼¼ÀÇ´ë)
ÈÞ½Ä 11¿ù 20ÀÏ 12:20~12:40 Break&ÃÑȸ ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 12:40~13:05 Predictive Biomarkers for Efficacy of Immune Checkpoint Blockades in Lung Cancer David Carbone(The Ohio State University)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:05~13:30 Translation Research in Immunotherapy for Lung Cancer Hidetoshi Hayashi(Kindai University)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:30~13:55 Is HyperProgression Real, or How Do We Prepare for It? ¼±Á¾¹«(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 13:55~14:20 If Less Is Good, More Is Better_Combination of ImmunoTx ÀÌ´ëÈ£(¿ï»êÀÇ´ë)
ÈÞ½Ä 11¿ù 20ÀÏ 14:20~14:30 Break ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 14:30~14:55 Evolution of Acquired Resistance to Targeted Therapies for Lung Cancer Aaron Hata(Massachusetts General HospitalHarvard Medical School)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 14:55~15:20 Treatment for Advanced ALK, ROS1-Rearranged Lung Cancer ±èµ¿¿Ï(¼¿ïÀÇ´ë)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 15:20~15:45 Treatment for Advanced MET, RET-Altered Lung Cancer Yasushi Goto(National Hospital Organization Kyushu Cancer Center)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 15:45~16:10 Treatment for Other Minor Mutations-Positive Advanced Lung Cancer °ÀºÁÖ(°í·ÁÀÇ´ë)
ÈÞ½Ä 11¿ù 20ÀÏ 16:10~16:20 Break ()
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 16:20~16:45 E-Cigarettes and Vaping-Related Lung Injury Jay H. Ryu(Mayo Clinic College of Medicine and Science)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 16:45~17:10 Current Status of Smoking Cessation with Heated Tobacco Products use in Japan Takahiro Tabuchi(Osaka international Cancer institute)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 17:10~17:35 Current status of smoking cessation program in Korea and COVID-19 risk in smokers õÀº¹Ì(ÀÌÈÀÇ´ë)
±³À°½Ã°£ 11¿ù 20ÀÏ ¿Â¶óÀÎ ½Ç½Ã°£ È»ó°ÀÇ 17:35~18:00 Pharmacotherapy for Smoking Cessation and Nicotine Dependence ÃÖÇý¼÷(°æÈñÀÇ´ë)